-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
![Image 04-04-2024 at 14.49](https://volition.com/wp-content/uploads/2024/04/Image-04-04-2024-at-14.49.jpeg)
How Nu.Q® Discover can support drug developers
- Share
- Tweet
- Share on Facebook
- Share
![Screenshot 2024-04-04 at 14.46.32](https://volition.com/wp-content/uploads/2024/04/Screenshot-2024-04-04-at-14.46.32-e1712250257566.png)
Watch highlights from a recent Biomarkers and Companion Diagnostic Conference 2024, where our Volition team showcased our Nu.Q® Discover assays to drug developers.
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields